Fresenius Medical Care AG research snapshot
FMS AI stock analysis as of the August 3, 2026 data cutoff reads Fresenius Medical Care as a recovering global dialysis platform with improving margins, a flat 2026 growth guide, and a stock that has climbed back above all major moving averages. At the July 31, 2026 close the ADR was $25.66, up from about $24 at the July 10 reference, with a market capitalization near $13.78 billion, cross-validated across StockAnalysis.com, Yahoo Finance, and Barchart. Q1 2026 revenue of EUR 4,612 million delivered 4% organic growth, and operating income excluding special items rose 10% at constant currency to EUR 467 million, lifting the margin to 10.1% from 9.4%, while reported net income fell 22% on EUR 166 million of FME25+ one-time costs. The company confirmed its FY2026 outlook of broadly flat revenue and operating income between positive and negative mid-single-digit growth, completed its first EUR 1.0 billion buyback in April 2026, and started a new EUR 1.0 billion program in May with a first tranche of up to EUR 600 million. The main offsets are U.S. reimbursement pressure after a proposed lower dialysis payment rate, net leverage of 2.6x, an RSI near 71 that is close to overbought, and analyst actions that include a BNP Paribas downgrade to Underperform with a $19.90 target. Q2 2026 results are scheduled for August 4, 2026, so they were not available at this data cutoff. This FMS AI stock analysis uses scenario ranges and source-backed checks, not a certain price prediction, and is for informational use only.
Current price
$25.66
Market cap
$13.78 billion
AI score
68 / 100
Rating
Global dialysis leader with 2025 recovery, a confirmed flat 2026 guide, buyback momentum, and reimbursement-sensitive valuation
Trend status
Bullish above the 20-day, 50-day, 100-day, and 200-day moving averages, with RSI near 71 approaching overbought after a recovery from the low-$23s
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Fresenius Medical Care runs a global kidney-care platform spanning dialysis clinics, dialyzers and machines, and related products, with recurring patient need and multi-country operating scale, serving about 289,923 patients in 3,539 clinics as of March 31, 2026. | High |
| Moat | Moat sources include clinic density, dialysis product manufacturing scale, physician and payer relationships, an installed base for machines and disposables, and regulatory know-how, with Morningstar describing about 35% share of the global dialysis products market. Reimbursement rules and regional competition still cap pricing power. | Medium-high |
| Management | CEO Helen Giza has driven FME25+ savings, EUR 50 million of additional savings in Q1 2026, debt reduction, portfolio focus, FME Reignite, 5008X CAREsystems rollout to about 100 U.S. clinics with more than 100,000 treatments, the completion of the first EUR 1.0 billion buyback in April 2026, and a new EUR 1.0 billion buyback program started in May 2026. | Medium-high |
| Financial trend | FY2025 revenue rose about 1.5% to EUR 19,628 million and reported net income rose 82% to EUR 978 million, while Q1 2026 showed 4% organic revenue growth, operating income excluding special items up 10% at constant currency to EUR 467 million at a 10.1% margin, basic EPS excluding special items up 16% at constant currency to EUR 0.91, and free cash flow up 94% to EUR 40 million, with net leverage at 2.6x. | High |
| Valuation | At $25.66, verified math shows about 13.8x TTM EPS of $1.86, roughly 11x forward adjusted EPS, about 0.84x book value, roughly 6.6x trailing free cash flow per ADR share, and about a 3.4% dividend yield on a $0.87 forward ADR dividend reference. | Medium-high |
| Technical trend | FMS closed at $25.66 on July 31, 2026, above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, after recovering from a late-June low near $23.05 that had put price below the 200-day, with RSI near 71 and 14-day stochastic near 93, which are approaching overbought, and a 52-week range of $20.02 to $27.64. | Medium |
| Risk level | Risk is moderate to high for a defensive healthcare name: Medicare and commercial reimbursement, a proposed lower U.S. dialysis payment rate, TDAPA transitions, labor inflation, clinic utilization, product mix, net leverage of 2.6x, FX translation on the ADR, the TAVNEOS EU marketing authorisation setback, and execution of FME Reignite all matter. | Medium-high |
| AI confidence | Descriptive confidence is high because company releases and market data align on the major facts, including the July 31 close, Q1 2026 results, leverage, and technical levels. Forecast confidence is lower because the 2026 guide is flat, Q2 2026 results were pending at the cutoff, and reimbursement policy can reprice the multiple. | High data confidence |
| Investment certainty | FMS looks like a watchlist value and turnaround name with cash generation, a dividend, and buyback support, not a high-certainty growth compounder at the current flat 2026 guide. | Medium |
FMS AI stock forecast
The FMS AI stock forecast is scenario math, not a guaranteed target. Using the August 3, 2026 research cutoff, a $25.66 ADR price, TTM EPS of $1.86, 537.13 million ADR shares, and a three-year model with 8%/4%/0% growth and 16x/12x/8x exit PE assumptions, the tested outcomes span about $37.50 bullish, $25.10 base, and $14.90 bearish before dividends. Q2 2026 results, scheduled for August 4, 2026, are a near-term catalyst for these scenarios.
$36 to $40
More likely if operating income holds near the upper half of the 2026 mid-single-digit band, free cash flow stays strong, net leverage stays at or below 2.6x, 5008X adoption supports product mix, U.S. reimbursement pressure eases, and the market values FMS near 16x higher EPS.
$23 to $27
More likely if revenue stays broadly flat, earnings grow only modestly from efficiency and mix, dividend and buyback capacity continue, and the ADR trades near 12x forward earnings with a mid-3% yield.
$14 to $17
More likely if reimbursement pressure from the proposed lower U.S. dialysis payment rate, labor costs, lower clinic utilization, FX, or leverage concerns compress earnings growth toward zero and the market re-rates FMS toward a high-single-digit PE.
FMS AI technical analysis
FMS AI technical analysis turned bullish as of the August 3, 2026 data cutoff. The ADR closed at $25.66 on July 31, 2026, above the 5-day moving average near $25.17, the 20-day near $24.42, the 50-day near $23.26, the 100-day near $22.86, and the 200-day near $23.39, after dipping below the 200-day in late June with a low near $23.05. Momentum is strong but near overbought, with 14-day RSI at 71.44 and 14-day stochastic readings above 90, and the 52-week range is $20.02 to $27.64.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $25.66 | StockAnalysis.com real-time quote at the July 31, 2026 close; Yahoo Finance intraday data was delayed at the cutoff, so the July 31 close is the reference. |
| 5-day moving average | $25.17 | Barchart reported the 5-day moving average near $25.17 on August 3, 2026, below the current price after a strong late-July advance. |
| Near support | $24.30 to $24.50 | The 20-day moving average near $24.42 is the first pullback support band, with the July 28 close near $24.75 adding context. |
| Deeper support | $23.20 to $23.45 | The 50-day moving average near $23.26 and the 200-day near $23.39 form a support cluster that held when price recovered from the low-$23s. |
| Resistance | $25.70 to $27.70 | Overhead supply starts near the recent high of $25.72 and the July 30 close of $25.70, extending into the 52-week high zone near $27.64. |
| Moving averages | 5-day $25.17, 20-day $24.42, 50-day $23.26, 100-day $22.86, 200-day $23.39 | Barchart and StockAnalysis snapshots agree on the moving averages, and price is above all five lines. |
| Momentum | RSI near 71, stochastic near 93 | Barchart and StockAnalysis both reported 14-day RSI near 71.44, and Barchart showed 14-day stochastic %K near 93.37 with %D near 89.21, signaling an overbought short-term condition. |
| Volume | Average volume near 0.56 million to 0.71 million ADR shares | Barchart listed 20-day average volume near 556,965 shares and 5-day near 711,360, while StockAnalysis listed 20-day average volume near 555,621, useful for judging breakouts. |
| Volatility | 14-day historic volatility near 19.9%, 50-day near 25.8% | Barchart reported 14-day historic volatility near 19.90% and 50-day near 25.77%, and the $20.02 to $27.64 52-week range shows both recovery and room for multiple compression. |
| Invalidation | Close below $24.30, then $23.20 | A decisive close below the 20-day moving average near $24.42 would weaken the short-term uptrend, and a break below the 50-day and 200-day cluster near $23.20 to $23.45 would turn the chart bearish. |
FMS AI trading strategy
The FMS AI trading strategy below is a rules-based planning framework for risk control, not personal investment advice. It combines price confirmation with evidence that Fresenius Medical Care can hold 2026 operating income, free cash flow, and leverage targets while advancing FME Reignite, and it should be paired with the Q2 2026 report scheduled for August 4, 2026.
Watch for FMS to hold the $24.30 to $24.50 support band and break above $25.70 on volume above the roughly 0.56 million to 0.71 million ADR share reference. Confirmation improves if Q2 2026 keeps operating income inside the guided mid-single-digit band and net leverage stays near 2.6x.
Treat a failed breakout back below $24.30 as a warning. A close below the 50-day and 200-day cluster near $23.20 invalidates the cleaner trend setup.
If FMS pulls back toward $23.20 to $24.50 without a reimbursement shock or leverage setback, compare the lower price with free cash flow, dividend capacity, FME Reignite progress, 5008X rollout milestones, and the Q2 2026 report.
Do not average down without a defined exit. A policy, labor, or FX reset matters more than the apparent discount after a rally that left RSI near overbought levels.
Track quarterly revenue versus the flat 2026 guide, operating income versus the EUR 2,212 million 2025 base, free cash flow, net debt and lease liabilities, net leverage, U.S. same-market treatment growth, Care Delivery and Care Enablement margins, dividend coverage, and buyback pace.
Reduce confidence if earnings depend mainly on one-time items or special item adjustments while organic volume, cash conversion, or leverage trend worsen, or if the proposed lower U.S. dialysis payment rate is finalized at a harsh level.
Investment research summary
Patients, payers, hospitals, and health systems pay Fresenius Medical Care for dialysis treatments, machines, dialyzers, and related kidney-care products because end-stage kidney disease care is medically necessary, recurring, and operationally complex at scale, with roughly 289,923 patients treated across 3,539 clinics as of March 31, 2026.
The moat is built from clinic networks, manufacturing scale in dialyzers and machines, an installed product base, physician relationships, payer contracting, and regulatory complexity, with an estimated 35% share of the global dialysis products market. It can narrow if reimbursement falls faster than productivity gains or product innovation lags peers.
The thesis fails if U.S. or international reimbursement resets lower after the proposed lower U.S. dialysis payment rate, clinic utilization stalls, labor inflation outruns rates, product mix disappoints, FX hurts ADR holders, leverage rises again above the 2.6x level, or FME Reignite savings fade after 2025.
Helen Giza and the leadership team have emphasized profitability recovery, FME25+ savings, debt reduction, portfolio focus, 5008X rollout, and capital returns, completing the first EUR 1.0 billion buyback early and launching a new EUR 1.0 billion program. The key test is whether the company can protect margins when 2026 revenue is guided as broadly flat.
Dialysis demand is tied to aging, diabetes, hypertension, and chronic kidney disease. The long-term need is durable, but growth is not a pure volume story because mortality, home dialysis mix, reimbursement policy, and product innovation all shape economics, and the TAVNEOS EU marketing authorisation setback shows product and regulatory risk.
At about 13.8x TTM EPS, 11x forward adjusted EPS, 0.84x book, roughly 6.6x trailing free cash flow, and a mid-3% dividend yield, FMS is priced more like a turnaround cash generator than a premium healthcare compounder. Margin of safety depends on holding leverage and earnings if growth stays flat and reimbursement pressure builds.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| FMS price | $25.66 at the July 31, 2026 close, with a 52-week range of $20.02 to $27.64 and an intraday reference near $24.96 on August 3, 2026 | StockAnalysis.com real-time quote and Yahoo Finance FMS quote | August 3, 2026 |
| Market capitalization | About $13.78 billion, computed as $25.66 x 537.13 million ADR shares; StockAnalysis reports $13.55 billion and Yahoo Finance reported about $13.4 billion intraday, a share-count basis variance | StockAnalysis.com statistics and Yahoo Finance key statistics | August 3, 2026 |
| Shares outstanding | 537.13 million ADR shares outstanding; company share capital is 268.56 million ordinary shares, with shares down about 2.3% year over year | Yahoo Finance key statistics and company share data | August 3, 2026 |
| Q1 2026 revenue | EUR 4,612 million, down 6% year over year but up 3% at constant currency and 4% organic, cross-validated across the Q1 2026 release and Yahoo Finance at 0.02% deviation | Fresenius Medical Care Q1 2026 press release | August 3, 2026 |
| Q1 2026 earnings | Operating income excluding special items of EUR 467 million up 10% at constant currency at a 10.1% margin, net income excluding special items of EUR 251 million up 9% at constant currency, basic EPS excluding special items of EUR 0.91 up 16% at constant currency, and reported net income of EUR 118 million down 22% on EUR 166 million of FME25+ one-time costs | Fresenius Medical Care Q1 2026 press release | August 3, 2026 |
| Q1 2026 cash flow and leverage | Operating cash flow of EUR 227 million up 39%, free cash flow of EUR 40 million up 94%, total net debt and lease liabilities of EUR 9,790 million, and net leverage of 2.6x versus 2.5x at Q4 2025 | Fresenius Medical Care Q1 2026 press release | August 3, 2026 |
| Q1 2026 operating metrics | About 289,923 patients treated in 3,539 dialysis clinics with 108,165 employees as of March 31, 2026, 5008X CAREsystems available in about 100 U.S. clinics with more than 100,000 treatments, and U.S. same market treatment growth of -0.4% | Fresenius Medical Care Q1 2026 press release | August 3, 2026 |
| FME25+ savings program | EUR 50 million of additional sustainable savings in Q1 2026, EUR 166 million of one-time costs, a 2026 plan of EUR 250 million savings and EUR 350 million one-time costs, and a target of EUR 1.2 billion total savings by the end of 2027, with 64 of up to 100 U.S. clinics exited | Fresenius Medical Care Q1 2026 press release | August 3, 2026 |
| Share buybacks | The first EUR 1.0 billion buyback was completed on April 30, 2026, buying back 24.8 million shares or 8.5% of share capital in less than one year, and a new EUR 1.0 billion program was announced May 26, 2026 with a first tranche of up to EUR 600 million launched May 28, 2026 | Fresenius Medical Care Q1 2026 release and buyback press releases | August 3, 2026 |
| FY2025 results | Revenue of EUR 19,628 million up 1.51% from EUR 19,338 million, reported net income of EUR 978 million up 81.88%, basic EPS of EUR 3.36, EPS excluding special items of EUR 4.28, free cash flow of EUR 1,782 million, and net leverage of 2.5x at year-end 2025 | Fresenius Medical Care FY2025 results release and StockAnalysis.com | August 3, 2026 |
| 2026 outlook | Broadly flat revenue and operating income in a positive to negative mid-single-digit range at constant currency excluding special items, against 2025 bases of EUR 19,628 million revenue and EUR 2,212 million operating income | Fresenius Medical Care Q1 2026 press release | August 3, 2026 |
| Valuation ratios | Verified PE about 13.8x on $1.86 TTM EPS, forward PE near 11x, PB about 0.84x, P/FCF about 6.6x on trailing free cash flow, PS near 0.62x, and dividend yield about 3.4% on a $0.87 forward ADR dividend reference | Yahoo Finance key statistics and financial_rigor.py | August 3, 2026 |
| Analyst consensus | Consensus rating Hold with an average price target near $25.60 to $25.74 across about 7 to 18 analysts, low near $18.11 to $18.20 and high near $37.86 to $38.06 | StockAnalysis.com forecast and Yahoo Finance analyst insights | August 3, 2026 |
| Analyst rating mix, July 2026 | 1 Strong Buy, 1 Buy, 2 Hold, 2 Sell, and 1 Strong Sell out of 7 analysts | StockAnalysis.com forecast recommendation trends | August 3, 2026 |
| Recent analyst actions | BNP Paribas downgraded FMS to Underperform from Neutral with a $19.90 target on July 28, 2026 expecting U.S. dialysis volumes to stay lower for longer, Citi raised its target to EUR 41 from EUR 40 with Neutral on about July 19, Bernstein initiated Market Perform with EUR 44.65 on about July 17, and Truist maintained Hold at $26 on May 21, 2026 | StockAnalysis.com forecast and news feed | August 3, 2026 |
| Technical indicators | 5-day SMA near $25.17, 20-day SMA near $24.42, 50-day SMA near $23.26, 100-day SMA near $22.86, 200-day SMA near $23.39, 14-day RSI near 71.44, 14-day stochastic near 93, 14-day ADX near 21.98, and 14-day historic volatility near 19.9% | Barchart and StockAnalysis.com technical snapshots | August 3, 2026 |
| Short interest | 2.92 million shares short, 0.20% of shares outstanding, and 4.51 days to cover | StockAnalysis.com statistics short selling | August 3, 2026 |
| Recent developments | A proposed lower U.S. dialysis reimbursement rate pressured the stock about a month before the cutoff, the CHMP recommended revoking the EU marketing authorisation for TAVNEOS (avacopan), Fresenius introduced TherapyWise analytics in July 2026, announced BEACON-US real-world evidence in July 2026, and launched the kinexus home dialysis platform earlier in 2026 | Yahoo Finance FMS news feed and company press releases | August 3, 2026 |
This FMS AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or an offer to buy or sell any security. Forecast ranges are scenario estimates based on public data as of the August 3, 2026 cutoff and can be wrong. The Q2 2026 report scheduled for August 4, 2026 was not available at the cutoff. Markets, reimbursement policy, currency translation, company results, and technical levels can change without notice. Do your own research and consider speaking with a licensed financial adviser before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
